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The purpose of this study is to provide an overview of the current status of research and 
commercial use of genetically modified (GM) crops worldwide and to quantify the 
importance of various policies, particularly intellectual property rights, to the spread of 
biotechnology research and commercial products.  Data collected for this paper show 
that most of the applied agricultural biotech research is conducted by the private sector 
of which a substantial portion is by multinational corporations.  Econometric analysis of 
this data finds that plant breeders’ rights and the ability to patent plants are associated 
with the spread of applied biotech research.   
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Plant breeders, biotechnology scientists,  and the firms that own biotechnology 
inventions try to charge royalties for use of their inventions or prevent people or firms 
from copying their inventions so that they can sell their invention at a high enough price 
to profit from their investment in research and development.  They control the use of 
their inventions by using legal means such as patents, plant breeder’s rights, and 
trademarks.  They also control their use by keeping inventions or key parts of their 
inventions secret, which in some countries are protected by trade secrecy law.  They 
also protect their inventions by biological means such as putting new characteristics into 
hybrid cultivars or including other technical means to prevent copying (i.e. the genetic 
use restriction techniques (GURTs) or Terminators).  In a few cases countries give one 
company a monopoly on the production and sales of a particular commodity. 
 
Laws to protect new plant varieties and biotech inventions, spread rapidly in developing 
countries in the late 1990s.  Their spread was accelerated by the intellectual property 
rights (IPRs) component of the World Trade Organization (WTO) agreement which 
required signatories to put in place some type of sui generis system of plant variety 
protection and patent protection for biotechnology inventions by 2000 (some developing 
countries have until 2005 to implement these IPRs).  As of December 1, 2001 49 states 
were members of the International Union for the Protection of New Varieties of Plants 
(UPOV), which indicates that they have some plant variety protection.  A number of 
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countries still exclude novel plants and animals from patent coverage, although many of 
them do allow patenting of novel microbes as is required by WTO. 
 
Although there is general agreement that utility patents have been an important stimulus 
to biotechnology research and product development in the U.S., there is no consensus 
about whether patents and other forms of intellectual property rights such as plant 
breeder’s rights are an important stimulus to biotechnology research elsewhere in the 
world.  In Europe patents on many types of biotechnologies were not allowed until the 
late 1990s.  Despite this there has been substantial investment in biotech research by 
private companies in Europe although not as much as in the U.S.  In developing 
countries there is considerable resistance to patents on biotechnology and to plant 
breeders rights.  Countries that have joined the World Trade Organization are obligated 
to pass some type of plant breeder’s rights and provide protection for biotechnology 
inventions. Many developing countries, however, have resisted actually passing such 
laws. People fear that both types of intellectual property rights will lead to new 
technology for farmers but are primarily means by which the major U.S. and European 
life science companies can dominate agricultural biotechnology and the seed industry in 
developing countries in the 21
st Century. 
 
The questions that this paper will try to answer are whether IPRs provide a stimulus to 
biotechnology research and technology transfer and who would benefit if a country’s 
IPRs were strengthened.  To answer these questions in the second section below, we 
first examine the spread of GM crops and biotechnology research.  Section three of the 
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paper discusses the econometric modeling used in this paper followed by data 
description from a cross section of countries.  The fourth section of the paper reports 
the results of econometric modeling of the relationship between IPRs and biotech 
research.  Finally, in section five we draw some conclusions for policy makers. 
 
The Spread of GM Crops and Biotechnology Research 
Commercial Use of GM Crops Worldwide 
Since 1996, the year in which genetically modified (GM) crops were first commercially 
planted in the U.S., there has been a steady increase in worldwide acreage planted.  In 
2000 roughly 60 million ha. were planted in eighteen countries up from 40 million ha. in 
12 countries in 1999.  Table 1 provides estimated area of commercial GM crops planted 
in 1999 and 2000 by country.  The U.S. grew the most at 40 million ha. followed by 
Argentina and Canada with more than 10 million ha. and 3 million ha., respectively.  All 
of the GM crops approved for commercial use have been marketed by the private 
sector, except in China where a number of commercially successful public GM varieties 
are in use.  China has been growing GM crops commercially since about 1990.  In 
2000, nearly 0.7 million ha. of GM crops were planted there.  In addition to these four 
countries, 14 other countries have planted between 1,000-125,000 ha. of GM crops.  
These include the European and Eastern European nations such as Bulgaria, France, 
Germany, Portugal, Romania, Spain, and Ukraine.  In addition, both the Russian 
Federation and former Yugoslav Republic expect to sell GM crops commercially in 
2001.  In South and Central America, Brazil, Chile, Mexico and Uruguay grew between 
3,000 and one million ha. in 2000 (although the million ha. of GM soybean in Brazil was 
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illegal).  Finally, commercial sales have been noted in Australia (at 125,000 ha.), Japan, 
Israel and South Africa (at 180,000 ha.).  Approximately ten different crops have been 
approved for commercial use worldwide.
1 
 
Research on GM Crops – Patterns of Research and Research Expenditure  
GM crop varieties were the culmination of a research process that identified useful 
genes, figured out how to transfer the genes into plants, found ways to make the gene 
express commercially useful traits in the plants, and then tested the GM crops to find 
whether they could be grown without causing problems for other crops, for the 
environment, or for human health.  Each time GM crops are moved from one country or 
region to another, the companies or government institutes have to test them to see 
whether they are adapted to local growing conditions and environments.  In many cases 
the gene will not work effectively unless it is transferred to local varieties by genetic 
engineering or by backcrossing the GM crop with local varieties.   
 
Precise estimates of plant biotech research that were required to produce the 
commercial biotech are not available.  Byerlee and Fischer (2000) have made some 
preliminary estimates of biotech research expenditure.  We have used their estimates to 
construct Table 2.  About 90 percent of the biotech research expenditure is in 
industrialized countries.  This is where both the public and private sectors conduct most 
of the basic research.  The private sector conducts a large amount of applied research 
                                                            
1 GM crops grown commercially include (in order of most-widely planted to least widely planted): herbicide tolerant 
(HT) soybean, Bt and some HT corn, Bt and some HT cotton, HT canola (collectively these four crops were more 
than 99 percent of the global GM crop area), insect resistant potato, viral resistant squash, viral resistant papaya , 
enhanced color and shelf-life carnation, sugar beet and HT lupin (only in Australia). Source: James (2000). 
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to develop new GM crop varieties.  In total there is more private than public research 
and the private research tends to be more applied.  In developing countries less money 
is spent and Byerlee and Fischer do not try to estimate the amount of private research 
that is conducted there.   
 
Biotech research in developing countries spans the entire spectrum of research from 
mapping plant and pathogen genomes in Brazil, China and India to very applied 
research to test whether GM crop varieties that were developed in the U.S. fit into the 
agricultural, climatic, and market conditions found in developing countries.  The field 
trials of GM crop varieties that are required to obtain biosafety approval in a country are 
the only way that we have been able to quantify the amount of the applied biotech 
research. 
 
Econometric Modeling of Biotech Research Investments 
The conceptual model explains the factors that influence the development of firms’ 
decisions about whether to conduct biotech research or not and how much research 
they should conduct.  The model is consistent with the theory that market size, 
technological opportunity and appropriability through IPRs or technology are important 
determinants of private research.  The rest of this section describes the model variables 
and tests empirically the importance of specific variables that can influence expected 
market size, technological opportunities and appropriability.   
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Biotechnology Research 
Agricultural biotechnology research and technology transfer are inseparable at present.  
Almost all of the key genes, which code for important economic characteristics as well 
as a number of key tools, which are essential to the construction of a GM crop, were 
developed in the U.S. or Europe.  However, none of these genes can be transferred to 
another country without considerable testing to ensure that the genes and the crop 
varieties that contain them actually work effectively in the new conditions.  Most genes 
will need to be transferred into locally adapted varieties before they can be sold 
commercially.   
 
Our measure of biotech research is the number of field trials of by private firms of their 
GM crops by country by year.  As discussed in section 2, data on research expenditure 
by private firms in any country is difficult to obtain and to obtain this type of data by 
country is impossible.  The actual spread of genetically engineered crops is available for 
a number of countries.  But it is not a good measure of companies’ research since in 
some countries such as Brazil GM soybeans have spread despite efforts by the 
government and Monsanto to prevent their spread.  The data on field trials of GM crops 
reflects the amount of research that is being conducted, although imperfectly.  Field 
trials that are conducted of GM crop varieties from private firms can be separated from 
public varieties.  Finally, they have been conducted in a large number of developing as 
well as industrialized countries, a much larger number of countries and years than 
actual adoption of GM crop varieties. 
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Expected Market Size 
The first generation of biotech products are either crop protection products like Bt cotton 
which is protected from certain important insect pests or herbicide tolerant crop varieties 
that allow for better control of weeds.  Both of these characteristics were embodied in 
the crop varieties and sold by the seed companies.  The data shows that insect 
resistance, herbicide tolerance and disease resistance are the focus of most of the field 
trials in industrialized and developing countries.  Thus, companies’ expectations about 
the size of markets that will be available in a country would be based on the current size 
of seed market and pesticide markets.  Companies make an estimate of how big these 
markets are and what share of these markets they could capture with their GM crop 
varieties that will be substitutes for conventional seeds plus pesticides. 
 
We have estimates of the value of seed markets (Seedmkt) for a sub sample of 37 
countries.  Data on the size of the pesticide market in a large number of countries is not 
available from public sources.  As an indicator of the size of the total input market 
relative to other countries we used the agricultural value added (AVA) as a proxy for 
market size. 
 
The innovating firm’s potential market size in many countries will depend on the extent 
of government intervention in the input markets.  In many developing countries and 
some formerly communist countries, the government still controls a substantial share of 
the seed and pesticide market.  Private firms may not consider the government’s share 
as potential part of their market for innovations.  In addition if the country has many 
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restrictions on the role of private firms and markets, these firms may further discount the 
possibility that the country will be a good market for innovations.  To capture this factor 
in our analysis we have included the Heritage Foundation’s (ECONFREE) index of 
economic freedom (Holmes et al., 1995-1999).  
 
Firms’ expectations about market size and when they will be able to enter the market 
will also be influenced by government regulation of biotechnology, which will reflect in 
part consumers’ attitudes.  When a country first allows a GM product to be used, firms’ 
expectations about their ability to sell more products in a market will increase.  We have 
included a variable (COMAPPR) for the year of first utilization as another explanatory 
variable influencing expected market size. 
 
Appropriability and IPRs 
The share of the market that an innovating firm might capture will depend in part on the 
strength of the intellectual property rights laws and their enforcement as well as the 
technical difficulty of copying the innovation.  If IPRs are stronger and it is difficult to 
copy the innovation, the innovating firm will expect to capture a larger share of the 
market.  GM crop varieties can be protected with plant variety certificates (PVCs) and 
the genes, markers, promoters and transformation techniques can be protected with 
utility patents in some countries.  Most countries do not allow inventors to both patent 
and use PVCs to protect plant varieties.  
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Measuring the strength of IPRs is a major problem.  An ideal measure would include 
both the breath of legal coverage and how effectively the laws are enforced.  One 
possibility would be to survey companies and get their perception of the strength of 
IPRs in different countries.  However, such a survey is beyond the scope of this study.  
Instead we have tried a number of measures of coverage of biotechnology including 
membership in UPOV (the French acronym for The International Union for the 
Protection of New Varieties of Plants), which indicates whether they have plant 
breeders’ rights to protect new varieties.  A second variable, PNP, was included to 
indicate whether the country’s patent law specifically excludes plants from being 
patented.  If plants are excluded, then inventors of new GM crop varieties have weaker 
property rights than if they are included.  We also tried the Park’s index (see Ginarte 
and Park 1997), which is based on what is included in IPR.  Finally, if a country is a 
signatory to the Patent Cooperation Treaty (PCTsign), an inventor in one country has a 
year from the time that he files during which he can file for a patent in other countries 
and have the original date of filing considered to be the date of filing in the other 
countries.  We would expect that countries that have signed this treaty are also 
countries with the strongest patent systems.  
 
The problem with the measures listed above is that IPRs are only useful if enforced and 
simply passing a law or a number of laws to protect IPRs is not sufficient to having a 
strong protection.  Lesser (2001) has developed an index of the strength of IPRs which 
attempts to include the ability to enforce patents by using an index of corruption.   
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Unfortunately, his index covers only developing countries.  We do not have any direct 
measure of enforcement of patents, but there are some measures of the strength of 
property rights in general, and we assume that stronger general property rights also will 
be correlated with the enforcement of IPRs.  We have used the rating of property rights 
(PropRts) by the Heritage Foundation as a possible measure of the strength of property 
rights in general and also IPRs.  Another way to measure the strength of IPRs would be 
measure how many patents are actually taken out in each country.  Firms will not bother 
to spend the time and money to obtain a patent in a country unless there is some way to 
enforce it.  Thus, more patents would mean that IPRs are stronger in that country.  The 
problem with this variable (BIOPAT) is that it may be related to research, the dependent 
variable, for reasons other than simply the strength of the patent system.  This could 
bias the results.   
 
Technological Opportunity 
Firms also base their research and development investment decisions on the cost to 
develop the new technology.  If the country has similar agricultural conditions as the 
U.S. the research cost of introducing GM technology that was developed in the U.S. 
might only be the cost of the field trials for agricultural suitability and environmental 
impact.  Therefore, we have included a dummy variable (CLIMATE), for temperate 
countries versus others.  If more research is needed to incorporate genes into locally 
adapted crop varieties, then the scientific capacity of the country to do applied and more 
basic research may be important.  As mentioned above, a few measures of private or 
public sector biotech research capacity are available.  However, it is possible to have 
  10  
some idea of biotech capacity based on the output of scientific papers published in a 
country in the plant biology area.  We have developed two variables that may measure 
this capacity – the number of plant biology publications in scientific journals abstracted 
by CAB International with authors at institutions in a specific country (CABABS1) and 
the number of publications published in journals that are located in the country 
(CABABS2).  Finally, we have the data on the applications for field trials (PUBTRIALS) 
of GM crop varieties submitted to the government by public research institutions or 
universities.  These reflect applied public biotechnology research.  More public biotech 
research capacity should lead to more private biotech research.    
 
The Econometric Model 
Data were collected over multiple time periods and multiple cross sectional units.  Given 
that the data series has both time series and cross section components, time series 
cross section (TSCS) regression methods were utilized to estimate the model.  Out of 
the three popular methods, Fuller and Battese method, Parks method and Da Silva 
method, based on the moving average component across time series, the Da Silva 
method was selected for the estimation (SAS/ETS1993). 
 
The Da Silva method can be viewed as a mixed variance-component moving average 
model.  The TSCS model for the Da Silva method can be written as 
 
Yi, t = ai + bt + β Xi,t + εi , t           ( 1 )  
 
  11  
Where, 
Yi, t   is the value of the dependent variable for the ith cross-section in the tth time  
period. 
ai  is a time invariant cross-sectional unit effect 
bt  is a cross-sectional unit invariant time effect 
β  is the slope parameter associated with the independent variable, Xi,t 
Xi,t  is the value of the independent variable for the ith cross section in the tth time 
Period 
εi,t  is a residual effect unaccounted for by the independent variable, the time effect, 
and the cross-sectional unit effect.  εi,t is assumed to be a finite moving average 
process. 
 
The empirical model specified to test for the determinants of plant biotechnology 
research and development can be represented as: 
 
Yi, t =   ai + bt + β1 SEEDMKTi,t + β2 AVAi,t + β3 ECONFREEi,t + β4 COMAPPRi,t +  
  β5 UPOVi,t + β6 PNPi,t + β7 PCTSIGNi,t + β8 PROPRTSi,t + β9 PUBTRIALSi,t +   
  β9 CABABS1i,t + β10 CLIMATEi,t + εi,t   
(2) 
Where, 
Yi, t   is the number of applications for field trials of GM crop varieties by 
private firms for the ith country in the tth time period. 
 
ai  is a time invariant cross-sectional unit effect 
bt  is a cross-sectional unit invariant time effect 
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βj  is the slope parameter associated with the independent variable,  
 X i,t, j=1,…10. 
 
SEEDMKTi,t  is the value of seed sales in $/year 
AVAi,t  is the value of agricultural value added products in $/year 
ECONFREEi,t  is the economic freedom index of Heritage foundation, ranges 1 through 
5, 1 implies the most freedom and 5 implies the least freedom 
 
COMAPPRi,t  is a dummy variable which equals 1 if commercial approval of GM crop 
varieties exists, 0 otherwise 
 
UPOVi,t  is a dummy variable which equals 1 if the country is a member of  The 
International Convention for the Protection of New Varieties of Plants, 0 
otherwise 
 
PNPi,t  is a dummy variable which equals 1 if plants are not specifically 
excluded from patent laws, 0 otherwise 
 
PCTSIGNi,t  is a dummy variable which equals 1 if the country is a member of Patent  
  Cooperation Treaty Signatory, 0 otherwise 
 
PROPRTSi,t  is the property rights index variable from the Heritage Foundation which 
ranges from 1 through 5, 1 implies the most protection, 5 implies the 
least protection 
 
PUBTRIALSi,t  is the number of applications for field trials of GM crop varieties by 
  public research institutions and universities.  
 
CABABS1i,t  is the number of biological publications published in a country 
CLIMATEi,t  is a dummy variable which equals 1 if temperate climate, 0 otherwise 
εi,t  is a residual effect unaccounted for by the independent variable, the time 
effect, and the cross-sectional unit effect.  εi,t is assumed to be a finite 
moving average process. 
 
Description of the Data 
As stated above, data on field trials of GM crops provides a measure for agricultural 
biotechnology near the end of the research process.  The dependent variable (Yi, t) is 
the total number of applications for field trials of GM crops that have been submitted 
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and approved in countries worldwide for each year.  Data has been collected from 1987 
to 2000 and includes 58 countries including 21 industrialized countries, 24 developing 
countries and 13 transitional economies.  Various sources such as Animal and Plant 
Health Protection Service (2001), Blanco (1998), Blume (2000), Artunduaga-Salas 
(2001), Australian Office of the Gene Technology Regulator, Biosafety Information 
Network Advisory Service (2001), Canada Food Inspection Agency, CONABIA, 
European Committee Joint Research Centre, Ghislain (2001), Hinrichsen (2000), 
Hungarian Agricultural Biosafety Center, James (1998), James and Krattiger (1996), 
Japan Ministry of Agriculture, Maoz (2001), Mexican Direccion General de Sanidad 
Vegetal, Moeljopawiro (1999), New Zealand Environmental Risk Management Authority, 
Oswaldo Cruz Foundation, Pray and Umali-Deininger (1998), Robert Koch Institute, and 
South African Directorate of Genetic Resources were used in collecting this data. 
 
Membership in International Convention for the Protection of New Varieties of Plants 
(UPOV) and Patent Cooperation Treaty Signatory (PCTsign) were collected from World 
Intellectual Property Organization, 2001.  Data on Plant Patent Laws (PNP) was 
collected from Hanellin (2000).  Property Rights Index from Heritage Foundation 
(PropRts) and Economic Freedom Index of Heritage Foundation (ECONFREE) were 
collected from Holmes, Johnson, and Kirkpatrick.  Data on Number of Biotech Patents 
approved in a country (BIOPAT) was collected from Delphion website.   
 
Data on Seed Sales (SEEDMKT) was collected from International Seed Federation.   
Agricultural value-added data (AVA), Gross Domestic Product (GDP) and GDP per 
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capita data were collected from the World Bank, World Development Indicators.  Data 
on Commercial Approval of GM varieties (COMAPPR) was collected from James and 
on Climate of a Country (CLIMATE) was collected from Times Atlas of the World.  Data 
on Biological Abstracts authored in a country (CABABS1) and Biological Publications 
published in a country (CABABS2) was collected from CAB International. 
 
Results   
The results of the regression analysis using the two data sets are shown in Tables 3 
and 4. The R-squared is above 0.7 in both specifications.  Almost all of the independent 
variables are significant and most have the expected signs.  
 
In the larger data set (Table 3) the market size variables performed as expected, bigger 
markets lead to more research.  The size of seed markets and the Agricultural Value 
Added variables both were positive and significant as expected.  The economic freedom 
index, which we expected to measure the size of the public sector and governments’ 
interference in the economy, was positive as expected (the more economic freedom the 
larger the expected market) but was not statistically significant.  The dummy variable for 
countries in which at least one GM crop variety had been approved for commercial use 
was positive, as evidence that when at least one GM product has been approved, firms’ 
expectations heighten that new products will also be approved. 
 
The key IPR variables had mixed results.  UPOV membership was the IPR variable that 
gave the most robust results – it had a consistently positive and significant impact on 
  15  
the number of field trials across different specifications and data sets.  The variable for 
whether plants are not excluded from the patent act (PNP) is negative and is highly 
significant.  This variable was expected to be positive, that is countries in which you can 
protect plants with patents should have a higher level of biotech research.  The negative 
sign occurred most likely because number countries that exclude plants are European 
countries, which do have strong PBRs but do not allow inventors to patent and obtain 
PBRs on plants.  Another variable that does not have the expected sign is the dummy 
variable for whether the country is a signatory to the patent cooperation treaty 
(PCTsign).  The negative sign on this variable suggests that holding other things 
constant, signing the treaty leads to less research, which seems unlikely.  
 
The technological opportunity variables also gave mixed results.  Applied public sector 
biotech research does appear to be an important factor influencing private firms’ 
decisions to do field trials. The variable (Pubtrials) was positive and significant in all of 
the specifications of the model.  The quantity of more basic biological research 
conducted in a country is less important.  In fact biological research as measured by 
publications (CABABS1) is negatively related to private biotech research.  A possible 
explanation for the negative relationship between publications and biotech research is 
that companies are induced to invest in applied research in countries with strong 
applied biotech research programs, but many of the countries that produce a lot of 
publications do not do much of the applied research that is useful to industry.  The 
temperate dummy variable (CLIMATE) is positive as expected implying that biotech 
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research is conducted in places where the climate is similar to the U.S. and Europe but 
it is not statistically significant.   
 
The second data set gives similar results but also allows us to test the biopatents 
variable in explaining biotech research (See Table 4).  Biopatents is positive and 
significant and as in the previous dataset UPOV is positive, but the other IPR variables 
are negative.  Comparing the other variables in specifications one and two indicates that 
adding biopatents changed the sign of one coefficient, the dummy for approval of any 
GM crop varieties went from positive to negative.  The other change is that the climate 
variable is now positive as expected. 
 
As discussed above the coefficient on biopatents variable could be biased by the fact 
that the number of biopatents is influenced not only by the strength of the patent 
system, but also by other omitted variables and by the actual amount of research 
expenditure by companies.  Thus, we have more confidence in the specifications in 
Table 3, but these results do provide some support to the argument that stronger 
patents lead to more research as measured by field trials.  The results of both data sets 
and specifications indicate that intellectual property rights do provide an incentive for 
private firms to conduct biotechnology research. 
 
Conclusions 
Plant biotechnology has had an important impact on agricultural productivity in a limited 
number of countries led by the U.S., Argentina, Canada, Brazil, China and South Africa. 
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Research on GM crops is much more widely spread and about 58 countries have 
reported field trials of GM crops. 
 
Economic theory and data from other industries suggest that firms decisions to perform 
research are based on expected market size of the products from research, on the 
ability to capture some of the value that the final users of the invention obtained, and 
finally on the availability of useful research and information from other research 
organizations like public universities and public research centers.  The results of the 
econometric analysis substantiates the hypotheses that the investments in applied 
biotechnology research are strongly influenced by: 
 
•  Plant variety protection and the strength of patent protection as measured by the 
number of patents on biotechnology products, 
 
•  Size of the seed market and the size of the agricultural sector, and 
 
•  Public sector research as measured by field trials conducted by public research 
organizations.  
 
The econometric study is the first quantitative evidence that explains the relationship 
between IPRs and international agricultural biotechnology research.  It indicates that 
IPRs may encourage applied biotechnology research.  The findings also emphasize the 
limits of IPRs.  If a country has a small market, no matter how strong its IPRs, firms may 
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not invest in research and technology transfer there.  If companies do not perform the 
research, the products of biotechnology – insect and disease resistant plants, will not be 
widely available to farmers. 
 
The results suggest that the impact of GM crops in selected countries generally 
confirms the results found in the U.S. and Canada that GM crops have been beneficial 
for farmers and consumers.  The results also suggest that governments in developing 
countries should not resist strengthening plant breeders’ rights and patents on 
biotechnology. 
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Table 1.   Estimated Area of Commercial GM Crops Planted in 
1999 and 2000. (in million ha.) 
 
Country 
  1999 2000 
United States 
  28.70 40.30 
Argentina 
  6.70 10.00 
Canada 










  0.10 0.15 
South Africa 
  0.10 0.20 
Mexico 
  <0.10 <0.10 
Spain 
  <0.10 <0.10 
France 
  <0.10 <0.10 
Portugal 
  <0.10 0.00 
Romania 
  <0.10 <0.10 
Ukraine 
  <0.10 <0.10 
Uruguay 0.00  <0.10 
Sources: Clive James (2000) plus Pray estimates for China and Brazil noted with "
*". 
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Table 2.   Estimated Expenditure on Crop Biotechnology 
Research. (in U.S. $ millions) 
 
   Biotech R&D 
Expenditure 





Industrialized    
         Private Sector Seed/Chemical 
         Multinationals 
         (includes some LDC R&D) 
 
1000-1500 40 
         Public Sector 
   900-1000 16 
Developing Countries    
         Public (from own resources) 
  100-150 5-10 
         Public (from foreign aid donors) 
   40-50 Na 
         CGIAR Centers 
  25-50 8 
         Private firms 
   ???  
World Total   2065-2730  
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Table 3.   Factors Influencing Biotech Research:  Regression 
Results (Dependent Variable:  Field Trials of Private 







 Intercept  -65.93 
 
-41.44 








Economic Freedom Index  9.24** 
(0.92) 
-- 




































R squared  .70  .70 
N   333  333 
 
Notes. Standard error in parentheses.  
** Statistically significant at the 5 percent confidence level. 
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Table 4.  Factors Influencing Biotech Research:  Regression 
Results (Dependent Variable:  Field Trials of GM 
























































R squared  .80  .71 
N   306  306 
 
** Statistically significant at the 5 percent level.  
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